Clinical trial
Etoposide, Oxaliplatin and Capecitabine in Advanced Hepatocellular Carcinoma…
NCT00351195 · Rigshospitalet, Denmark, Other · Terminated
Key facts
| NCT number | NCT00351195 |
|---|---|
| Title | Etoposide, Oxaliplatin and Capecitabine in Advanced Hepatocellular Carcinoma (HCC) |
| Official title | A Phase II Study of Etoposide, Oxaliplatin and Capecitabine in Patients With Advanced HCC |
| Lead sponsor | Rigshospitalet, Denmark, Other |
| Collaborators | Morten Ladekarl, MD, DMSc., Dept. of Oncology, Århus Sygehus, Århus |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hepatocellular Carcinoma |
| Intervention type | Drug |
| Interventions | Etoposide, Oxaliplatin, Capecitabine |
| Enrollment | 39 |
| Start date | Feb 1, 2006 |
| Completion | Apr 1, 2007 |
| First posted | Jul 12, 2006 |
| Last update posted | Aug 26, 2008 |
| Countries | Denmark |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: